PTK2 and non-small cell lung carcinoma: Future studies incorporating RNA sequencing and (phospho)-proteomics to map mechanistic pathways will be important to elucidate FAK regulation and clarify how its inhibition reverses resistance, ultimately guiding the optimization of therapeutic strategies for NSCLC patients.